J B Chemicals and Pharmaceuticals Ltd
JB Pharma's GHG Emissions Data Preview
In 2024, JB Pharma completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy), and Scope 3 (indirect emissions across the value chain).
JB Pharma has also provided a category-level breakdown for 9 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Scope 2 | ||||
Unspecified Calculation Method | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
Total Scope 3 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data.  | 0000000 |
This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
Insights into JB Pharma's Operational Emissions
In 2024, the total operational greenhouse gas (GHG) emissions of JB Pharma amounted to 47,672 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).
Compared to 2023, the total operational greenhouse gas (GHG) emissions of JB Pharma decreased by 13.92%, showing that the company has made progress in taking action to reduce the climate impact of its operations.
JB Pharma's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are JB Pharma's Scope 1 emissions?
In 2024, the total Scope 1 emissions of JB Pharma were 8,691 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Has JB Pharma reduced its Scope 1 emissions over time?
Since 2021, JB Pharma's Scope 1 emissions have increased by 2.92%, reflecting a rising long-term trend in Scope 1 emissions over time.
Compared to the previous year (2023), JB Pharma's Scope 1 emissions decreased by 13.92%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.
What are JB Pharma's Scope 2 emissions?
In 2024, JB Pharma reported Scope 2 greenhouse gas (GHG) emissions of 38,981 tCOâ‚‚e without specifying the calculation method.
Has JB Pharma reduced its Scope 2 emissions over time?
Since 2021, JB Pharma's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have decreased by 12.69%, reflecting a declining long-term trend in Scope 2 emissions over time.
Compared to the previous year (2023), JB Pharma's Scope 2 emissions (Unspecified Calculation Method) fell by 13.91% in 2024, showing that the company has made progress in taking action to reduce the climate impact of its energy consumption.
What methodology does JB Pharma use for Scope 2 reporting?
In 2024, JB Pharma reported its Scope 2 emissions using an unspecified methodology.
JB Pharma's Scope 2 Emissions Over Time
- Total Scope 2 (Unspecified Calculation Method)
Insights into JB Pharma's Value Chain Emissions
In 2024, JB Pharma reported 188,961 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.
The 2024 disclosure of JB Pharma includes a breakdown across 9 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2023, demonstrating consistent Scope 3 emissions reporting coverage year over year.
JB Pharma's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are JB Pharma's Scope 3 emissions?
In 2024, JB Pharma reported total Scope 3 emissions of 188,961 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Approximately 99.98% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0.02% came from downstream activities like product use, distribution, and end-of-life treatment.
Compared to the previous year (2023), JB Pharma's Scope 3 emissions increased by 38.09%, suggesting that the company faced challenges in reducing emissions across its value chain.
What categories of Scope 3 emissions does JB Pharma disclose?
In 2024, JB Pharma reported emissions for 9 out of the 15 Scope 3 categories defined by the GHG Protocol.
This partial disclosure allows for some insight into the company's indirect impacts.
What are the main sources of JB Pharma's Scope 3 emissions?
In 2024, the largest contributors to JB Pharma's Scope 3 emissions were:
- Purchased Goods and Services (Cat. 1): 106,010 tCOâ‚‚e (56.1%)
- Fuel- and Energy-Related Services (Cat. 3): 28,699 tCOâ‚‚e (15.19%)
- Downstream Transportation and Distribution (Cat. 9): 22,480 tCOâ‚‚e (11.9%)
JB Pharma's Scope 3 Emissions by Categories
Insights into JB Pharma's Total Carbon Footprint
In 2024, JB Pharma reported a total carbon footprint of 236,633 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 23.11% increase compared to 2023, suggesting a rise in emissions across its operations or value chain.
The largest contributor to JB Pharma's total carbon footprint was Scope 3 emissions, accounting for 79.85% of the company's total carbon footprint, followed by Scope 2 emissions at 16.47%.